Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Payables (2019 - 2025)

Allogene Therapeutics' Payables history spans 7 years, with the latest figure at $3.7 million for Q3 2025.

  • For Q3 2025, Payables fell 32.82% year-over-year to $3.7 million; the TTM value through Sep 2025 reached $3.7 million, down 32.82%, while the annual FY2024 figure was $5.4 million, 8.53% down from the prior year.
  • Payables for Q3 2025 was $3.7 million at Allogene Therapeutics, down from $4.9 million in the prior quarter.
  • Across five years, Payables topped out at $14.9 million in Q1 2021 and bottomed at $3.7 million in Q3 2025.
  • The 5-year median for Payables is $9.7 million (2022), against an average of $9.0 million.
  • The largest annual shift saw Payables soared 106.63% in 2021 before it crashed 62.5% in 2025.
  • A 5-year view of Payables shows it stood at $10.3 million in 2021, then surged by 35.45% to $13.9 million in 2022, then tumbled by 57.54% to $5.9 million in 2023, then dropped by 8.53% to $5.4 million in 2024, then crashed by 31.42% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Payables are $3.7 million (Q3 2025), $4.9 million (Q2 2025), and $5.1 million (Q1 2025).